Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Iovance Biotherapeutics Inc 825 INDUSTRIAL ROAD SUITE 100 SAN CARLOS CA 94070 USA

www.iovance.com Employees: 838 P: 650-260-7120

Sector:

Medical

Description:

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.

Key Statistics

Overview:

Market Capitalization, $K 1,147,238
Enterprise Value, $K 1,032,548
Shares Outstanding, K 396,968
Float, K 356,080
% Float 89.70%
Short Interest, K 105,255
Short Float 26.51%
Days to Cover 7.57
Short Volume Ratio 0.35
% of Insider Shareholders 10.30%
% of Institutional Shareholders 77.03%

Financials:

Annual Sales, $ 164,070 K
Annual Net Income, $ -372,180 K
Last Quarter Sales, $ 67,460 K
Last Quarter Net Income, $ -91,250 K
EBIT, $ -407,460 K
EBITDA, $ -374,110 K

Growth:

1-Year Return -31.89%
3-Year Return -48.57%
5-Year Return -88.32%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 19.50%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.25 on 11/06/25
Next Earnings Date 02/24/26 [BMO]
Earnings Per Share ttm -1.20
EPS Growth vs. Prev Qtr 24.24%
EPS Growth vs. Prev Year 10.71%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-100 on 09/27/13

IOVA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -55.25%
Return-on-Assets % -43.11%
Profit Margin % -226.84%
Debt/Equity 0.00
Price/Sales 4.99
Price/Cash Flow N/A
Price/Book 1.62
Book Value/Share 1.77
Interest Coverage -1.45
60-Month Beta 0.76
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar